Initiatives to address social determinants of health are likely to positively change the health care landscape, and better patient education can contribute to more favorable care choices says Ken Cohen, MD, director of translational research for Optum Care.
Initiatives to address social determinants of health are likely to positively change the health care landscape, and better patient education can contribute to more favorable care choices says Ken Cohen, MD, director of translational research for Optum Care.
Transcript
How should data be balanced with what the patient thinks they need?
That's a critically important question. Patients continue to conflate more care with better care, and nothing can be farther from the truth. That's the fault of the medical system because we have not done a very good job of educating patients. The solution to that is sophisticated, shared decision-making modules that can actually teach patients in a way that they can understand and participate with what are the real-world outcomes of the care that they're seeking? When you show them that real-world outcome data, by and large, they will choose the correct care. So, we can do this, but we just haven't done an adequate job to date.
What is the role of data currently doing to address disparities of care?
We're not doing enough, but mostly we're not doing enough not because there's not a desire to improve it. I think across the health care system is recognition of the need to improve. The problem is we haven't measured it adequately at this point, so we don't know where to improve. That's changing. Very, very quickly people are adapting to that and beginning to rigorously measure social determinants of health. Once we have an accurate landscape to know where there are deficiencies and how those can be improved, then resources are available to be applied to that, and I think the landscape will change very quickly.
Taletrectinib Recommended in NCCN Guidelines for ROS1-Positive NSCLC
July 31st 2025Taletrectinib was added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology as a preferred option for the first-line and subsequent treatment of advanced ROS1-positive non–small cell lung cancer (NSCLC).
Read More
Trump Directs Pharma Companies on Cutting Drug Prices Under Most-Favored-Nation Order
July 31st 2025President Donald Trump has sent letters to pharmaceutical companies, aiming to compel them to lower drug prices in the US to match the lowest prices offered in other developed nations, a move that could significantly reduce costs and disrupt the current system of pharmacy benefit managers.
Read More